Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium - 05/01/19
Doi : 10.1016/S1470-2045(18)30858-1
Eva Clemens, MSc a, b, *, Marry M van den Heuvel-Eibrink, MD a, *, Renée L Mulder, PhD a, c, Leontien C M Kremer, MD a, c, Melissa M Hudson, MD d, f, Roderick Skinner, PhD g, Louis S Constine, ProfMD h, Johnnie K Bass, PhD e, Claudia E Kuehni, MD i, j, Thorsten Langer, MD k, Elvira C van Dalen, PhD a, c, Edith Bardi, MD l, Nicolas-Xavier Bonne, MD m, Penelope R Brock, MD n, Beth Brooks, MSc e, o, q, Bruce Carleton, PharmD p, r, Eric Caron, MSN f, Kay W Chang, MD s, Karen Johnston, MN t, Kristin Knight, MSc u, Paul C Nathan, MD v, Etan Orgel, MD w, x, Pinki K Prasad, MD y, z, Jan Rottenberg, MD aa, Katrin Scheinemann, MD ab, ac, ad, Andrica C H de Vries, MD a, b, Thomas Walwyn, MBBS ae, af, Annette Weiss, PhD i, ag, Antoinette am Zehnhoff-Dinnesen, ProfMD ah, Richard J Cohn, ProfMBBCh t, ai, †, Wendy Landier, PhD aj, ⁎, † 
on behalf of the
on behalf of the
International Guideline Harmonization Group ototoxicity group‡
a Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
b Department of Pediatric Hematology and Oncology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, Netherlands
c Department of Pediatric Oncology, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
d Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA
e Rehabilitation Services, St Jude Children’s Research Hospital, Memphis, TN, USA
f Department of Epidemiology and Cancer Control, St Jude Children’s Research Hospital, Memphis, TN, USA
g Department of Pediatric and Adolescent Hematology/Oncology and Children’s Hematopoietic Stem Cell Transplant Unit, Great North Children’s Hospital and Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK
h Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York, NY, USA
i Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
j Department of Pediatrics, Children’s University Hospital of Bern, University of Bern, Bern, Switzerland
k Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany
l Department of Pediatrics and Adolescent Medicine, Kepler Universitätsklinikum, Linz, Austria
m University of Lille, CHU Lille, Otology and Otoneurology, Lille, France
n Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
o Audiology and Speech Pathology Department, British Columbia’s Children’s Hospital, Vancouver, BC, Canada
p Pharmaceutical Outcomes Programme, British Columbia’s Children’s Hospital, Vancouver, BC, Canada
q School of Audiology and Speech Sciences, University of British Columbia, Vancouver, BC, Canada
r Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
s Department of Otolaryngology, Stanford University, Palo Alto, CA, USA
t Kids Cancer Centre, Sydney Children’s Hospital, High Street, Randwick, NSW, Australia
u Department of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children’s Hospital, Oregon Health and Science University, Portland, OR, USA
v Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
w Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
x Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
y Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA
z Division of Pediatric Hematology/Oncology, Children’s Hospital of New Orleans, New Orleans, LA, USA
aa Department of Otolaryngology and Head and Neck Surgery, St Ann’s University Hospital Brno, Masaryk University, Brno, Czech Republic
ab Division of Pediatric Hematology/Oncology, Hospital for Children and Adolescents, Cantonal Hospital Aarau, Aarau, Switzerland
ac Division of Pediatric Hematology/Oncology, University for Children’s Hospital Basel, Basel, Switzerland
ad Division of Pediatric Hematology/Oncology, McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada
ae Department of Pediatric and Adolescent Oncology, Perth Children’s Hospital, Nedlands, WA, Australia
af School of Medicine, University of Western Australia, Perth, WA, Australia
ag Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
ah Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University of Münster, Münster, Germany
ai School of Women’s and Children’s Health, University of New South Wales Medicine, Sydney, NSW, Australia
aj Institute for Cancer Outcomes and Survivorship, Department of Pediatrics, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, AL, USA
* Correspondence to: Dr Wendy Landier, Institute for Cancer Outcomes and Survivorship, Department of Pediatrics, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA Institute for Cancer Outcomes and Survivorship Department of Pediatrics School of Medicine University of Alabama at Birmingham Birmingham AL 35233 USA
Summary |
Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
Le texte complet de cet article est disponible en PDF.Plan
© 2019
Elsevier Ltd. Tous droits réservés.
Vol 20 - N° 1
P. e29-e41 - janvier 2019 Retour au numéro
Article précédent
- Exploring and comparing adverse events between PARP inhibitors
- Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman
- Childhood cancer burden: a review of global estimates
- Nickhill Bhakta, Lisa M Force, Claudia Allemani, Rifat Atun, Freddie Bray, Michel P Coleman, Eva Steliarova-Foucher, A Lindsay Frazier, Leslie L Robison, Carlos Rodriguez-Galindo, Christina Fitzmaurice
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?